Daily BriefsUnited States

Daily Brief United States: Futu Holdings Ltd, Black Knight Inc, Vertex Pharmaceuticals, Kulicke And Soffa Industries,, Micron Technology, Ethereum, Bitcoin Pro, Splunk Inc and more

In today’s briefing:

  • Futu (FUTU US / 3588 HK): Dual Primary Listing, Stock Connect & Potential HSCI/HSTECH Inclusion
  • MergerTalk:Why Black Knight May Be As Safe As Houses Even If Regulators Stop Its Merger With ICE
  • Vertex Pharmaceuticals (VRTX US): A High-Quality Deep Pocket Biotech Must-Have for Every Investor
  • Breaking Estimates Short Candidates: Kulicke & Soffa, Kronos, Marvell Tech, Montauk Renewables
  • Micron Fiscal Q1: Short-Term Pain For Long-Term Gain
  • Smartkarma Webinar | Is There Still Hope for Crypto in 2023?
  • Developing Economies: A Proven Use Case for Crypto
  • Splunk Is A Rare Tech Growth Opportunity For 2023

Futu (FUTU US / 3588 HK): Dual Primary Listing, Stock Connect & Potential HSCI/HSTECH Inclusion

By Brian Freitas


MergerTalk:Why Black Knight May Be As Safe As Houses Even If Regulators Stop Its Merger With ICE

By Robert Sassoon

  • We think that a ~40% spread overstates the risk of this deal not moving to completion. 
  • The horizontal integration aspects of this transaction can be remedied, but this is a largely vertical merger transaction which regulators may struggle to prove will lead to monopolistic behavior.
  • Even if the  ICE merger is ultimately blocked,  BKI has other supporting factors that could drive upside – an attractive valuation and a potential revival of interest from other parties 

Vertex Pharmaceuticals (VRTX US): A High-Quality Deep Pocket Biotech Must-Have for Every Investor

By Tina Banerjee

  • Vertex Pharmaceuticals (VRTX US), the global leader in cystic fibrosis treatment, has a broad and deep clinical pipeline across multiple modalities. Each of its clinical programs represents a multibillion-dollar opportunity.  
  • MRNA drug candidate for treating the remaining 5,000 CF patients who cannot benefit from existing therapies, is set to enter clinic. Drug candidate for acute pain is in late-stage trial.
  • Regulatory submission for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia in U.S., EU and UK are expected to be completed by 1Q23.

Breaking Estimates Short Candidates: Kulicke & Soffa, Kronos, Marvell Tech, Montauk Renewables

By Eric Fernandez, CFA

  • This model finds companies facing recent sharp cuts in estimates. These shorts can have very disparate characteristics.
  • The key judgement involves whether the negative revisions are temporary or if they are indications of ongoing weakness in the business. 
  • Breaking Estimates stocks often continue to decline after the cuts.  This week we flag:  Kulicke & Soffa, Kronos, Marvell Tech, Montauk Renewables

Micron Fiscal Q1: Short-Term Pain For Long-Term Gain

By Kevin George

  • Micron Technology, Inc. reported fiscal Q1 2023 earnings and announced cost-cutting measures.
  • Macroeconomic trends are still a drag, according to the company.
  • The company also announced cost cutting measures for the next year’s fiscal year.

Smartkarma Webinar | Is There Still Hope for Crypto in 2023?

By Smartkarma Research

Is there still hope for Crypto in 2023? In the next webinar, we speak with Insight Provider Edward Wu on just that, as he shares with us the landscape of the Crypto industry in 2023. From the problems with the current crypto industry, to Ethereum Layer 2 solutions, Edward will share with us his thoughts in this next episode of our Webinar Wednesdays. Have any burning questions about Crypto, DeFi trading or Ethereum Layer 2 solutions? Get them answered in the live Q&A that will conclude the session. 

The webinar will be hosted on Wednesday, 4 January 2023, 17:00 SGT/HKT.

Edward Wu is an experienced financial professional with strong research experience in macroeconomics, credit as well as corporate banking. He is a true believer in the future of Crypto/DeFi and foresee widely adoption of tokenization of real-world assets. He is currently actively researching in the crypto field, mainly focused on DeFi, DAO governance, and tokenomic design.


Developing Economies: A Proven Use Case for Crypto

By Kaiko

  • Some people think of crypto as purely an investment opportunity. A highly volatile asset class that comes with risk, but eventually the returns will be worth it.
  • However, this perception is somewhat naive, as it ignores one of crypto’s biggest use cases: financial freedom.
  • The concept of financial freedom is hard to grasp for the privileged of us living in Europe or the US – despite record levels of inflation, we are not financially oppressed, and we can bank on our savings being relatively intact next year.

Splunk Is A Rare Tech Growth Opportunity For 2023

By Kevin George

  • Splunk is stronger with Q3 earnings and guidance. The company is shadowed by takeover talk.
  • The company has a strong cloud market make it a buy. The firm is shadowing by takeover talks.
  • The firm has been in the news for more than two years.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars